| References: |
AZD8186 is and inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K), with potential antineoplastic activity. Upon administration, PI3Kbeta inhibitor AZD8186 selectively inhibits the activity of PI3Kbeta in the PI3K/Akt/mTOR signaling pathway, which may result in a decrease of tumor cell proliferation. It also induces cell death in PI3K-expressing cancer cells. By specifically targeting class I PI3K beta, this agent may be more efficacious and less toxic than pan PI3K inhibitors. PI3K-mediated signaling is often dysregulated in cancer cells and contributes to increased tumor cell growth, survival, and tumor resistance to a variety of antineoplastic agents. AZD8186 is currently under Phase I clinical trials. For the detailed information of AZD8186, the solubility of AZD8186 in water, the solubility of AZD8186 in DMSO, the solubility of AZD8186 in PBS buffer, the animal experiment (test) of AZD8186, the cell expriment (test) of AZD8186, the in vivo, in vitro and clinical trial test of AZD8186, the EC50, IC50,and affinity,of AZD8186, For the detailed information of AZD8186, the solubility of AZD8186 in water, the solubility of AZD8186 in DMSO, the solubility of AZD8186 in PBS buffer, the animal experiment (test) of AZD8186, the cell expriment (test) of AZD8186, the in vivo, in vitro and clinical trial test of AZD8186, the EC50, IC50,and affinity,of AZD8186, Please contact DC Chemicals. |
